Andreas Grauer

Andreas Grauer

Auto-generated profile, based on publicly available information

Andreas Grauer

Federation Bio, South San Francisco, California

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in Journal of Bone and Joint Surgery
Verified
Journal Article
Open access
ESEmil H. Schemitsch
Emil H. Schemitsch
TMTheodore Miclau
Theodore Miclau
TKTheofilos Karachalios
Theofilos Karachalios
LNLauren L. Nowak
Lauren L. Nowak
PSParag Sancheti
Parag Sancheti
MBMohit Bhandari
Mohit Bhandari
Background: Romosozumab is a bone-forming antibody that increases bone formation and decreases bone resorption. We conducted a double-blinded, randomized, phase-2, dose-finding trial to evaluate the effect of romosozumab on the clinical outcomes of open reduction and internal fixation of intertrochanteric or femoral neck hip fractures. Methods: Patients (55 to 94 years old) were randomized 2:3:3:3 to receive 3 subcutaneous injections of romosozumab (70, 140, or 210 mg) or a placebo postoperatively on day 1 and weeks 2, 6, and 12. The primary end point was the difference in the mean timed “Up & Go” (TUG) score over weeks 6 to 20 for romosozumab versus placebo. Additional end points included the time to radiographic evidence of healing and the score on the Radiographic Union Scale for Hip (RUSH). Results: A total of 332 patients were randomized: 243 to receive romosozumab (70 mg, n = 60; 140 mg, n = 93; and 210 mg, n = 90) and 89 to receive a placebo. Although TUG scores improved during the study, they did not differ significantly between the romosozumab and placebo groups over weeks 6 to 20 (p = 0.198). The median time to radiographic evidence of healing was 16.4 to 16.9 weeks across treatment groups. The RUSH scores improved over time across treatment groups but did not differ significantly between the romosozumab and placebo groups. The overall safety and tolerability profile of romosozumab was comparable with that of the placebo. Conclusions: Romosozumab did not improve the fracture-healing-related clinical and radiographic outcomes in the study population. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

18 May 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PMPamela N. Munster
Pamela N. Munster
AGAndrew E Greenstein
Andrew E Greenstein
GFGini F. Fleming
Gini F. Fleming
EBErkut Borazanci
Erkut Borazanci
MSManish R. Sharma
Manish R. Sharma
JSJasgit C. Sachdev
Jasgit C. Sachdev
Purpose: Chemotherapy resistance remains a major problem in many solid tumors, including breast, ovarian, and pancreatic cancer. Glucocorticoids are one potential driver of chemotherapy resistance as they can mediate tumor progression via induction of cell-survival pathways. We investigated whether combining the selective glucocorticoid receptor (GR) modulator relacorilant with taxanes can enhance antitumor activity. Patients and Methods: The effect of relacorilant on paclitaxel efficacy was assessed in OVCAR5 cells in vitro and in the MIA PaCa-2 xenograft. A phase 1 study of patients with advanced solid tumors was conducted to determine the recommended phase 2 dose of relacorilant + nab-paclitaxel. Results: In OVCAR5 cells, relacorilant reversed the deleterious effects of glucocorticoids on paclitaxel efficacy (P < 0.001). Compared with paclitaxel alone, relacorilant + paclitaxel reduced tumor growth and slowed time to progression in xenograft models (both P < 0.0001). In the heavily pretreated phase 1 population [median (range) of prior regimens: 3 (1–8), prior taxane in 75.3% (55/73)], 33% (19/57) of response-evaluable patients achieved durable disease control (≥16 weeks) with relacorilant + nab-paclitaxel and 28.6% (12/42) experienced longer duration of benefit than on prior taxane (up to 6.4×). The most common dose-limiting toxicity of the combination was neutropenia, which was manageable with prophylactic G-CSF. Clinical benefit with relacorilant + nab-paclitaxel was also associated with GR-regulated transcript-level changes in a panel of GR-controlled genes. Conclusions: The observed preclinical, clinical, and GR-specific pharmacodynamic responses demonstrate that selective GR modulation with relacorilant combined with nab-paclitaxel may promote chemotherapy response and is tolerable. Further evaluation of this combination in tumor types responsive to taxanes is ongoing.

9 November 2019 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
JTJunichi Takada
Junichi Takada
RDRajani Dinavahi
Rajani Dinavahi
AMAkimitsu Miyauchi
Akimitsu Miyauchi
EHEtsuro Hamaya
Etsuro Hamaya
THToshiyasu Hirama
Toshiyasu Hirama
AGAndreas Grauer
Andreas Grauer

1 April 1992 in Bone and Mineral
Verified
Journal Article
Closed access
AGAndreas Grauer
Andreas Grauer
FRFriedhelm Raue
Friedhelm Raue
HRHans H. Reinel
Hans H. Reinel
HSHans Gerhard Schneider
Hans Gerhard Schneider
JSJuliane Schroth
Juliane Schroth
RZReinhard Ziegler
Reinhard Ziegler

1 July 1990 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
MLM. Lazaretti-Castro
M. Lazaretti-Castro
AGA. Grauer
A. Grauer
FRF. Raue
F. Raue
RZR. Ziegler
R. Ziegler

21 June 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CLCraig B. Langman
Craig B. Langman
DADean Assimos
Dean Assimos
MBMelanie Blank
Melanie Blank
JCJuan Calle
Juan Calle
AGAndreas Grauer
Andreas Grauer
OWon behalf of the Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup)
on behalf of the Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup)
Enteric hyperoxaluria is a medical condition characterized by elevated urinary oxalate excretion due to increased gastrointestinal oxalate absorption. Causative features include fat malabsorption and/or increased intestinal permeability to oxalate. Enteric hyperoxaluria has long been known to cause nephrolithiasis and nephrocalcinosis, and, more recently, an association with CKD and kidney failure has been shown. Currently, there are no US Food and Drug Administration–approved therapies for enteric hyperoxaluria, and it is unclear what end points should be used to evaluate the efficacy of new drugs and biologics for this condition. This study represents work of a multidisciplinary group convened by the Kidney Health Initiative to review the evidence supporting potential end points for clinical trials in enteric hyperoxaluria. A potential clinical outcome is symptomatic kidney stone events. Potential surrogate end points include (1) an irreversible loss of kidney function as a surrogate for progression to kidney failure, (2) asymptomatic kidney stone growth/new stone formation observed on imaging as a surrogate for symptomatic kidney stone events, (3) urinary oxalate and urinary calcium oxalate supersaturation as surrogates for the development of symptomatic kidney stone events, and (4) plasma oxalate as a surrogate for the development of the clinical manifestations of systemic oxalosis. Unfortunately, because of gaps in the data, this Kidney Health Initiative workgroup was unable to provide definitive recommendations. Work is underway to obtain robust information that can be used to inform trial design and medical product development in this space.